IS7889A - Lagskipt tafla, sem inniheldur pravastatín og aspirín, og aðferð - Google Patents

Lagskipt tafla, sem inniheldur pravastatín og aspirín, og aðferð

Info

Publication number
IS7889A
IS7889A IS7889A IS7889A IS7889A IS 7889 A IS7889 A IS 7889A IS 7889 A IS7889 A IS 7889A IS 7889 A IS7889 A IS 7889A IS 7889 A IS7889 A IS 7889A
Authority
IS
Iceland
Prior art keywords
aspirin
pravastatin
layer containing
tablet containing
containing pravastatin
Prior art date
Application number
IS7889A
Other languages
English (en)
Other versions
IS2877B (is
Inventor
Abebe Admassu
Benkerrour Loutfy
Galley Olivier
Quinet Francoise
Timmins Peter
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32505946&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS7889(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of IS7889A publication Critical patent/IS7889A/is
Publication of IS2877B publication Critical patent/IS2877B/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IS7889A 2002-12-11 2005-06-10 Lagskipt tafla, sem inniheldur pravastatín og aspirín, og aðferð IS2877B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/316,424 US20040115265A1 (en) 2002-12-11 2002-12-11 Multilayered tablet containing pravastatin and aspirin and method
PCT/US2003/038774 WO2004052289A2 (en) 2002-12-11 2003-12-03 Multilayered tablet containing pravastatin and aspirin

Publications (2)

Publication Number Publication Date
IS7889A true IS7889A (is) 2005-06-10
IS2877B IS2877B (is) 2014-04-15

Family

ID=32505946

Family Applications (1)

Application Number Title Priority Date Filing Date
IS7889A IS2877B (is) 2002-12-11 2005-06-10 Lagskipt tafla, sem inniheldur pravastatín og aspirín, og aðferð

Country Status (17)

Country Link
US (1) US20040115265A1 (is)
EP (1) EP1581194B1 (is)
JP (1) JP2006511520A (is)
AT (1) ATE401061T1 (is)
AU (1) AU2003297689A1 (is)
CY (1) CY1108414T1 (is)
DE (1) DE60322264D1 (is)
DK (1) DK1581194T3 (is)
ES (1) ES2308040T3 (is)
IS (1) IS2877B (is)
MY (1) MY140947A (is)
NO (1) NO338696B1 (is)
PL (1) PL206190B1 (is)
PT (1) PT1581194E (is)
SI (1) SI1581194T1 (is)
TW (1) TWI361700B (is)
WO (1) WO2004052289A2 (is)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2316456T (pt) 2003-04-29 2017-09-05 Orexigen Therapeutics Inc Composições para afetar a perda de peso compreendendo naltrexona e bupropion
US8163797B2 (en) * 2003-12-31 2012-04-24 Actavis Elizabeth Llc Method of treating with stable pravastatin formulation
JP2008526771A (ja) * 2004-12-30 2008-07-24 ジェンザイム コーポレーション 高リン酸血症のための亜鉛含有処置
US20060251722A1 (en) * 2005-05-03 2006-11-09 Novavax, Inc. Multi-component vitamin and mineral supplement for the optimal absorption of components
US8986669B2 (en) * 2005-09-02 2015-03-24 Genzyme Corporation Method for removing phosphate and polymer used therefore
WO2007056405A2 (en) * 2005-11-08 2007-05-18 Genzyme Corporation Magnesium-containing polymers for the treatment of hyperphosphatemia
DK2135603T3 (da) 2005-11-22 2013-03-25 Orexigen Therapeutics Inc Sammensætninger og fremgangsmåder til øgning af insulinsensitivitet
WO2007072060A2 (en) * 2005-12-23 2007-06-28 Cipla Limited Particles comprising a core containing a hmg-coa reductase inhibitor and coated with a film
ATE489079T1 (de) 2005-12-29 2010-12-15 Osmotica Kereskedelmi Es Szolgaltata Kft Mehrschichtige tablette mit dreifacher freisetzungskombination
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
EP2043627A2 (en) * 2006-07-05 2009-04-08 Genzyme Corporation Iron(ii)-containing treatments for hyperphosphatemia
US8765178B2 (en) * 2006-07-19 2014-07-01 Watson Laboratories, Inc. Controlled release formulations and associated methods
CN101588795A (zh) * 2006-11-09 2009-11-25 奥雷西根治疗公司 包含中间快速溶解层的分层药物制剂
AU2007319472B2 (en) 2006-11-09 2013-01-17 Nalpropion Pharmaceuticals Llc Methods Of Administering Weight Loss Medications
PL2134351T3 (pl) 2007-03-13 2017-10-31 Jds Therapeutics Llc Sposoby i kompozycje do przedłużonego uwalniania chromu
WO2009002867A2 (en) * 2007-06-26 2008-12-31 Nutrition 21, Inc. Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
JP5654873B2 (ja) 2007-10-12 2015-01-14 フエリング・インターナシヨナル・センター・エス・アー 医薬品を製造する方法
US20110144145A1 (en) 2008-05-30 2011-06-16 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
AU2011203867B2 (en) 2010-01-11 2015-12-03 Nalpropion Pharmaceuticals Llc Methods of providing weight loss therapy in patients with major depression
TR201005325A2 (tr) 2010-06-30 2012-01-23 Bi̇lgi̇ç Mahmut Atorvastatin ve aspirin içeren farmasötik formülasyonlar
KR20120068277A (ko) * 2010-12-17 2012-06-27 한미사이언스 주식회사 ＨＭＧ－ＣｏＡ 환원효소 억제제 및 아스피린을 포함하는 약제학적 복합제제
US8718837B2 (en) * 2011-01-28 2014-05-06 Intouch Technologies Interfacing with a mobile telepresence robot
EP2858640B1 (en) 2012-06-06 2020-03-25 Nalpropion Pharmaceuticals LLC Composition for use in a method of treating overweight and obesity in patients with high cardiovascular risk
EP2810644A1 (en) * 2013-06-06 2014-12-10 Ferrer Internacional, S.A. Oral formulation for the treatment of cardiovascular diseases
GB2564295A (en) 2016-02-11 2019-01-09 Nutrition 21 Llc Chromium containing compositions for improving health and fitness
JP7109748B2 (ja) * 2018-12-11 2022-08-01 日本ジェネリック株式会社 アジルサルタンとアムロジピンベシル酸塩含有固形製剤及び固形製剤の製造方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4590183A (en) * 1985-04-22 1986-05-20 Sterling Drug Inc. Gastric cytoprotection with sodium thiosulfate in oral administration of aspirin
JP3172749B2 (ja) * 1992-02-17 2001-06-04 ライオン株式会社 イブプロフェン含有製剤
IT1255522B (it) * 1992-09-24 1995-11-09 Ubaldo Conte Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita'
IT1264517B1 (it) * 1993-05-31 1996-09-24 Ekita Investments Nv Compressa farmaceutica atta al rilascio in tempi successivi dei principi attivi in essa veicolati
FR2772615B1 (fr) * 1997-12-23 2002-06-14 Lipha Comprime multicouche pour la liberation instantanee puis prolongee de substances actives
US6235311B1 (en) * 1998-03-18 2001-05-22 Bristol-Myers Squibb Company Pharmaceutical composition containing a combination of a statin and aspirin and method
BR9908911A (pt) * 1998-03-19 2001-10-02 Bristol Myers Squibb Co Sistema bifásico e processo de distribuição por liberação controlada de substâncias farmacêuticas de alta solubilidade
US6669955B2 (en) * 2001-08-28 2003-12-30 Longwood Pharmaceutical Research, Inc. Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin

Also Published As

Publication number Publication date
EP1581194B1 (en) 2008-07-16
ES2308040T3 (es) 2008-12-01
WO2004052289A3 (en) 2005-03-24
EP1581194A4 (en) 2006-03-15
NO338696B1 (no) 2016-10-03
NO20052734L (no) 2005-07-07
AU2003297689A8 (en) 2004-06-30
CY1108414T1 (el) 2014-02-12
WO2004052289A2 (en) 2004-06-24
DK1581194T3 (da) 2008-10-20
PT1581194E (pt) 2008-09-24
IS2877B (is) 2014-04-15
TWI361700B (en) 2012-04-11
SI1581194T1 (sl) 2008-12-31
US20040115265A1 (en) 2004-06-17
NO20052734D0 (no) 2005-06-07
AU2003297689A1 (en) 2004-06-30
PL377265A1 (pl) 2006-01-23
MY140947A (en) 2010-02-12
PL206190B1 (pl) 2010-07-30
JP2006511520A (ja) 2006-04-06
ATE401061T1 (de) 2008-08-15
DE60322264D1 (de) 2008-08-28
TW200505432A (en) 2005-02-16
EP1581194A2 (en) 2005-10-05

Similar Documents

Publication Publication Date Title
IS7889A (is) Lagskipt tafla, sem inniheldur pravastatín og aspirín, og aðferð
AU2003251642A1 (en) Laser markable carrier unit
PE20000349A1 (es) Composicion farmaceutica que contiene una combinacion de una estatina y aspirina
AU2003295370A1 (en) Gas layer formation materials
MXPA02012638A (es) Peliculas de barrera de alta humedad.
ATE279915T1 (de) Mehrschichttablette zur verabreichung einer fixen kombination von tramadol und diclofenac
AR017749A1 (es) Estructura de multiples estratos
DE50007387D1 (de) Strahlungshärtbare verbundschichtplatte oder -folie
AU2003236831A1 (en) Materials containing multiple layers of vesicles
PE20120542A1 (es) Formas de dosificacion solidas de valsartan, amlodipina e hidroclorotiazida y metodo para elaborarlas
MX2007010224A (es) Uso de un catalizador de varias capas para producir anhidrido ftalico.
AU2002328410A1 (en) Adhesive for gas barrier laminates and laminated films
AU2003234610A1 (en) Higher layer bonding of multiple access lines for carrier grade access
ATE374425T1 (de) Zweilagige schutzschicht
DE50006328D1 (de) Transparente biaxial orientierte polyolefinfolie
WO2008096679A1 (ja) 透過型スクリーン
AU2002356226A1 (en) Multilayer sealing materials or peelable seals
WO2007147125A3 (en) Tetracycline package formulations
AU2003285237A8 (en) Barrier layer for thick film dielectric electroluminescent displays
TH69755A (th) ยาเม็ดชนิดหลายชั้นซึ่งมีพราวาสเตติน และแอสไพริน และวิธี
WO2005081651A3 (en) Housebuilding, wall element and method related thereto
PL371753A1 (pl) Sposób wytwarzania domieszkowanych warstw epitaksjalnych InxAlyGa1-x-yN, domieszkowana warstwa epitaksjalna InxAlyGa1-x-yN i półprzewodnikowa struktura wielowarstwowa zawierająca warstwę epitaksjalną InxAlyGa1-x-yN, dla której 1 ˛ x > 0.001 a 0.999 ˛ y > 0
AU2003244318A1 (en) Transparent laminated film having barrier property and method for production thereof
AU2003266636A1 (en) Laminate comprising silver layer and, formed thereon, layer for stabilizing the same
AU2002362467A1 (en) Multi-layer articles including a fluoroelastomer layer and a barrier layer and method of making the same